Experimental cancer drug INCA00186 tested in early trial
NCT ID NCT04989387
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This early-phase study tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in 57 people with advanced solid tumors like head and neck or gastrointestinal cancers. The goal was to check safety, dosing, and early signs of effectiveness. The trial was terminated, so final results are not available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cambridge University Hospitals Nhs Foundation Trust
Cambridge, CB2 0QQ, United Kingdom
-
Carolina Bio-Oncology Institute, Pllc
Huntersville, North Carolina, 28078, United States
-
Cliniques Universitaires Ucl Saint-Luc
Brussels, 01200, Belgium
-
Emory University
Atlanta, Georgia, 30322, United States
-
Erasmus Mc Cancer Institute
Rotterdam, 3015GD, Netherlands
-
Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Fundacion Jimenez Diaz University Hospital
Madrid, 28040, Spain
-
Ghent University Hospital
Ghent, 09000, Belgium
-
Guys and St Thomas Nhs Foundation Trust
London, SE1 9RT, United Kingdom
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Hospital Clinico Universitario Virgen de La Victoria
Málaga, 29010, Spain
-
Hospital General Universitario Vall D Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, 28223, Spain
-
Imperial College Healthcare Nhs Trust - Hammersmith Hospital
London, W12 0HS, United Kingdom
-
Innsbruck University Hospital
Innsbruck, A-6020, Austria
-
Institut Catala Doncologia Ico - Hospital Duran I Reynals Location
Barcelona, 199203, Spain
-
Institut Jules Bordet
Brussels, B-1070, Belgium
-
Landeskrankenhaus Salzburg
Salzburg, 05020, Austria
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, 1066 CX, Netherlands
-
Radboud University Nijmegen Medical Center
Nijmegen, 6525 GA, Netherlands
-
South Texas Accelerated Research Therapeutics
San Antonio, Texas, 78229, United States
-
The Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
The Christie Nhs Foundation Trust Uk
Manchester, M20 4BV, United Kingdom
-
The Royal Marsden Nhs Foundation Trust - Chelsea
Sutton, SM2 5PT, United Kingdom
-
Universitair Ziekenhuis (Uz) Leuven
Leuven, 03000, Belgium
-
Universitair Ziekenhuis Antwerpen (Uza)
Edegem, 02650, Belgium
-
University Medical Center Groningen
Groningen, 9713GZ, Netherlands
-
University Medical Center Utrecht
Utrecht, 3584 CX, Netherlands
-
University of Maryland-Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
-
Vanderbilt Medical Center
Nashville, Tennessee, 37232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCA00186 (an experimental drug) given alone or with retifanlimab and/or INCB106385
What this could lead to
If successful, this could point toward a new treatment option for certain advanced solid tumors, especially head and neck or gastrointestinal cancers.
What could go wrong
This is a very early (Phase 1) trial that was terminated, so results are limited. The drug may not prove effective or safe, and it is only tested in people with specific tumor types.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.